Lineage Cell Therapeutics
LCTX
LCTX
107 hedge funds and large institutions have $71.2M invested in Lineage Cell Therapeutics in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
9% less funds holding
Funds holding: 118 → 107 (-11)
17% less capital invested
Capital invested by funds: $85.9M → $71.2M (-$14.7M)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
Holders
107
Holding in Top 10
3
Calls
$40K
Puts
$43K
Top Buyers
| 1 | +$1.1M | |
| 2 | +$368K | |
| 3 | +$277K | |
| 4 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$156K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$135K |
Top Sellers
| 1 | -$655K | |
| 2 | -$430K | |
| 3 | -$281K | |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$274K |
| 5 |
BlackRock
New York
|
-$140K |